REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

HLB bioStep Co. Ltd. (South Korea)

Main Activities: Research and Development in the Physical, Engineering, and Life Sciences
Full name: HLB bioStep Co. Ltd. Profile Updated: July 04, 2023
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English Download a sample report

Knotus Co.,Ltd. is engaged in provision of clinical research services. The company also offers products such as antibiotic drugs, respiratory drugs, cardiovascular drugs, vitamin tablets and other related products. Knotus Co.,Ltd. was incorporated in 2012 and is based in Incheon, South Korea.

Headquarters
38, Academy-ro 79beon-gil Yeonsu-gu Incheon
Incheon; Incheon;

Contact Details: Purchase the HLB bioStep Co. Ltd. report to view the information.

Basic Information
Total Employees:
Purchase the HLB bioStep Co. Ltd. report to view the information.
Outstanding Shares:
Purchase the HLB bioStep Co. Ltd. report to view the information.
Registered Capital:
Purchase the HLB bioStep Co. Ltd. report to view the information.
Incorporation Date:
April 19, 2012
Key Executives
Purchase this report to view the information.
CEO
Purchase this report to view the information.
Non-Executive Independent Director
Purchase this report to view the information.
Non-Executive Independent Director
Purchase this report to view the information.
Auditor
Purchase this report to view the information.
Managing Director
Company Performance
Financial values in the chart are available after HLB bioStep Co. Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
20.49%▲
Total operating revenue
20.49%▲
Operating profit (EBIT)
-34.42%▼
EBITDA
-17.56%▼
Net Profit (Loss) for the Period
N/A
Total assets
82.06%▲
Total equity
5.35%▲
Operating Profit Margin (ROS)
-8.29%▼
Net Profit Margin
N/A
Return on Equity (ROE)
N/A
Debt to Equity Ratio
111.81%▲
Quick Ratio
9.85%▲
Cash Ratio
1.19%▲

Similar companies

Cj Cheiljedang Corporation
 
Green Cross Corporation
Hyundai Autron Co.,Ltd.
 
Gm Technical Center Korea Co.,Ltd.
Sk Biopharmaceuticals Co.,Ltd.
 
Ecopro Hn Co., Ltd.
Nh Special Purpose Acquisition 17 Company
 
Young In Frontier Co.,Ltd.
Dream Cis Inc.
 
Corestemchemon Inc.
Psomagen, Inc.
 

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo